REED ELIZABETH E — SEC insider filings
SEC reporting owner CIK 1283303. 37 insider filings on record with FilingPulse; latest filed 2026-09-17.
Transaction summary — filings shown
Covers all 37 filings on record, filed 2020-09-22 to 2026-09-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 52 legs across 35 filings — 251,665 shares, $8,936,972 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 51.
- Largest priced transaction: sale of 37,500 shares @ $41.07 ($1,540,125) in Travere Therapeutics, Inc., filed 2026-04-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | Chief Legal Officer and GC | 37 | — | 52 legs · 251,665 sh · $8,936,972 | 51 |
Insider filings — REED ELIZABETH E
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 37,500 @ $15.46 · Sale (S): 21,926 @ $62.03 · Sale (S): 13,874 @ $62.63 · Sale (S): 1,400 @ $63.69 · Sale (S): 300 @ $65.31 · Option exercise (M): 37,500 (derivative) @ $0 | EDGAR |
| 2026-05-06 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 20,000 @ $17.96 · Sale (S): 20,000 @ $45 · Option exercise (M): 4,250 @ $0 · Sale (S): 2,174 @ $46.65 · Sale (S): 2,076 @ $43.95 · Option exercise (M): 20,000 (derivative) @ $0 · +2 more | EDGAR |
| 2026-04-15 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 14,000 @ $0 · Option exercise (M): 10,000 @ $19.08 · Option exercise (M): 20,000 @ $17.96 · Option exercise (M): 7,500 @ $15.46 · Sale (S): 37,500 @ $41.07 · Sale (S): 7,215 @ $41.93 · +5 more | EDGAR |
| 2026-04-02 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 10,000 @ $15.46 · Sale (S): 10,000 @ $30 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-03-18 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 10,000 @ $19.08 · Sale (S): 10,000 @ $28.09 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 10,000 @ $19.08 · Sale (S): 5,679 @ $27.50 · Sale (S): 4,321 @ $28.26 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 2,485 @ $32.07 · Sale (S): 509 @ $32.74 | EDGAR |
| 2026-02-03 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 25,110 @ $0 · Sale (S): 7,175 @ $32.12 · Grant/award (A): 66,960 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 10,000 @ $19.08 · Sale (S): 10,000 @ $27.34 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-09-24 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 10,000 @ $19.08 · Sale (S): 10,000 @ $25 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-05-05 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 4,920 · Sale (S): 4,920 @ $21.05 · Option exercise (M): 4,920 (derivative) @ $0 | EDGAR |
| 2025-02-12 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 8,000 · Sale (S): 8,000 @ $23.53 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 21,500 @ $0 · Sale (S): 8,951 @ $19.78 · Grant/award (A): 58,000 (derivative) @ $0 | EDGAR |
| 2025-01-23 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 2,437 @ $19.46 | EDGAR |
| 2024-09-09 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 6,750 @ $0 · Sale (S): 4,387 @ $11.52 | EDGAR |
| 2024-02-02 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 25,000 @ $0 · Sale (S): 2,174 @ $8.53 · Sale (S): 2,590 @ $8.86 · Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2024-01-25 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 2,062 @ $8.96 | EDGAR |
| 2023-09-05 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 3,300 @ $0 · Sale (S): 1,815 @ $14.71 | EDGAR |
| 2023-05-12 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 825 @ $16.59 | EDGAR |
| 2023-02-02 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 20,250 @ $0 · Sale (S): 2,590 @ $22.25 · Grant/award (A): 54,500 (derivative) @ $0 · Grant/award (A): 6,750 (derivative) @ $0 | EDGAR |
| 2023-01-26 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 2,062 @ $21.50 | EDGAR |
| 2022-05-12 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 900 @ $21.51 · Sale (S): 1,050 @ $21.51 | EDGAR |
| 2022-02-02 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 9,840 @ $0 · Sale (S): 1,350 @ $27.40 · Grant/award (A): 39,360 (derivative) @ $0 · Grant/award (A): 9,840 (derivative) @ $0 · Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2022-01-26 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 2,250 @ $24.98 | EDGAR |
| 2022-01-12 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 5,000 @ $0 · Sale (S): 5,000 @ $27.40 | EDGAR |
| 2021-08-17 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 4,500 @ $0 · Sale (S): 1,407 @ $17.12 | EDGAR |
| 2021-05-13 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 1,625 @ $19.14 · Sale (S): 1,625 @ $19.46 | EDGAR |
| 2021-02-09 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 2,250 @ $31.41 · Sale (S): 2,250 @ $31.58 | EDGAR |
| 2021-02-05 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 4,500 @ $0 | EDGAR |
| 2021-02-03 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 2,500 @ $28.91 · Sale (S): 675 @ $28.91 | EDGAR |
| 2021-02-02 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 5,000 @ $0 · Sale (S): 2,500 @ $30.75 · Sale (S): 675 @ $30.75 | EDGAR |
| 2021-01-25 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 15,000 @ $0 · Grant/award (A): 57,500 (derivative) @ $0 | EDGAR |
| 2021-01-07 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 688 @ $26.65 · Sale (S): 688 @ $27.01 | EDGAR |
| 2020-11-17 | 4 | Travere Therapeutics, Inc. (RTRX) | Sale (S): 2,500 @ $23.98 | EDGAR |
| 2020-11-13 | 4 | Retrophin, Inc. (RTRX) | Grant/award (A): 5,000 @ $0 · Sale (S): 2,500 @ $23.62 | EDGAR |
| 2020-09-23 | 4 | Retrophin, Inc. (RTRX) | Sale (S): 1,500 @ $18.48 | EDGAR |
| 2020-09-22 | 4 | Retrophin, Inc. (RTRX) | Grant/award (A): 3,000 @ $0 · Sale (S): 1,500 @ $18.59 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-21 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1283303 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs